X0303 4 2011-06-27 0000887151 Capstone Therapeutics Corp. CAPS 0001055947 BVF PARTNERS L P/IL 900 N. MICHIGAN AVE., SUITE 1100 CHICAGO IL 60611 0 0 1 0 0000918923 BIOTECHNOLOGY VALUE FUND L P 900 N. MICHIGAN AVE., SUITE 1100 CHICAGO IL 60611 0 0 0 1 See Explanation of Responses 0001102444 BIOTECHNOLOGY VALUE FUND II LP 900 N. MICHIGAN AVE., SUITE 1100 CHICAGO IL 60611 0 0 0 1 See Explanation of Responses 0001132245 BVF INVESTMENTS LLC 900 N. MICHIGAN AVE., SUITE 1100 CHICAGO IL 60611 0 0 0 1 See Explanation of Responses 0001056807 BVF INC/IL 900 N. MICHIGAN AVE., SUITE 1100 CHICAGO IL 60611 0 0 1 0 0001233840 LAMPERT MARK N 900 N. MICHIGAN AVE., SUITE 1100 CHICAGO IL 60611 0 0 1 0 Common Stock 2011-06-27 4 P 0 14800 .25 A 1218288 I See Explanation of Responses Common Stock 2011-06-28 4 P 0 7150 .25 A 1225438 I See Explanation of Responses Common Stock 2011-06-29 4 P 0 3450 .2483 A 1228888 I See Explanation of Responses Common Stock 2011-06-27 4 P 0 1700 .25 A 820100 I See Explanation of Responses Common Stock 2011-06-28 4 P 0 4800 .25 A 824900 I See Explanation of Responses Common Stock 2011-06-29 4 P 0 2400 .2483 A 827300 I See Explanation of Responses Common Stock 2011-06-27 4 P 0 40200 .25 A 3155200 I See Explanation of Responses Common Stock 2011-06-28 4 P 0 18450 .25 A 3173650 I See Explanation of Responses Common Stock 2011-06-29 4 P 0 7100 .2483 A 3180750 I See Explanation of Responses This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), BVF Investments, L.L.C. ("BVFLLC"), BVF Partners L.P. ("Partners"), BVF Inc., and Mark Lampert (collectively the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a section 13G group that collectively owns more than 10% of the Issuer's oustanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of his or its pecuniary interest therein. Represents shares of Common Stock owned directly by BVF. As the general partner of BVF, Partners may be deemed to beneficially own the shares of Common Stock owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the shares of Common Stock owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the shares of Common Stock owned directly by BVF. Represents shares of Common Stock owned directly by BVF2. As the general partner of BVF2, Partners may be deemed to beneficially own the shares of Common Stock owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the shares of Common Stock owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the shares of Common Stock owned directly by BVF2. Represents shares of Common Stock owned directly by BVFLLC. As the manager of BVFLLC, Partners may be deemed to beneficially own the shares of Common Stock owned directly by BVFLLC. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the shares of Common Stock owned directly by BVFLLC. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the shares of Common Stock owned directly by BVFLLC. Units may represent aggregation of daily trade activity. Details regarding individual execution amounts and prices are available upon request BVF Partners L.P., By: BVF Inc., its GP, By: /s/ Mark N. Lampert, President 2011-06-29 BIOTECHNOLOGY VALUE FUND, L.P. By: BVF Partners L.P., its GP, By: BVF Inc., By: /s/ Mark N. Lampert, President 2011-06-29 BIOTECHNOLOGY VALUE FUND II, L.P., By: BVF Partners L.P., its GP, By: BVF Inc., By: /s/ Mark N. Lampert, President 2011-06-29 BVF INVESTMENTS, L.L.C., By: BVF Partners L.P., its Manager, By: BVF Inc., By: /s/ Mark N. Lampert, President 2011-06-29 BVF INC., By: /s/ Mark N. Lampert, President 2011-06-29 Mark N. Lampert, By: /s/ Mark N. Lampert 2011-06-29